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Dermato®brosarcoma protuberans is a malignant
mesenchymal tumor originating in the dermis.
Although it is locally aggressive and recurs unless
completely excised, it only rarely metastasizes. In
this study, we investigated the mechanisms of
increased proliferation of dermato®brosarcoma pro-
tuberans cells. The cells showed increased DNA
synthesis in serum-free medium, which was demon-
strated by the incorporation of [3H]-thymidine.
Increased DNA synthesis of dermato®brosarcoma
protuberans cells was abolished by genistein, a tyro-
sine kinase inhibitor, or by PD98059, a speci®c extra-
cellular signal related kinase pathway inhibitor, but
not by calphostin C, a protein kinase C inhibitor.
Immunoblotting analysis of dermato®brosarcoma
protuberans cells using a speci®c antibody against
phosphorylated extracellular signal related kinase
(Thr202/Tyr204) showed that extracellular signal
related kinase was expressed as constitutively phos-
phorylated molecules in dermato®brosarcoma protu-
berans cells. Immuno¯uorescence analysis showed
that the kinase was constitutively located in the
nucleus of the cells. Furthermore, transfection of the
dominant negative mutant extracellular signal related
kinase into dermato®brosarcoma protuberans cells
abolished the increased mitogenic activity of the
cells. These results suggest that an extracellular signal
related kinase dependent pathway is implicated in
the increased mitogenic activity of dermato®brosar-
coma protuberans cells. Key words: ®broblasts/kinase
inhibitor/platelet-derived growth factor receptor/signal
transduction. J Invest Dermatol 119:954±960, 2002
D
ermato®brosarcoma protuberans (DFSP) is a rare
malignant mesenchymal tumor that arises in the
dermis and is characterized by latency in its initial
detection, slow in®ltrative growth, and local recur-
rence if not adequately treated (Laskin, 1992).
Within the family of related ®broblastic tumors, the pathobiologic
potential of DFSP is considered to be intermediate between that of
dermato®broma and malignant ®brous histiocytoma.
Deregulation of cell proliferation is an important event under-
lying the development of human neoplasia and can be determined
by changes in factors controlling different steps in the cell growth
process (Cohen and Ellewein, 1990). Growth factors acting
through autocrine or paracrine mechanisms have been proposed
to play an important role in cancer development and progression
(Weinstein, 1987).
Recent studies reported that DFSP is characterized by speci®c
cytogenic features: a translocation t(17; 22)(q22;q13) and super-
numerary ring chromosomes derived from t(17; 22) (Pedeutour
et al, 1993; 1996). Furthermore, Shimon et al reported that the
DFSP-speci®c t(17; 22) translocation creates a molecular aberration
by juxtaposing different portions of the a1(I)collagen (COL1A1)
gene to the second exon of the platelet-derived growth factor b-
chain (PDGFB) gene (Simon et al, 1997). The resulting chimeric
gene encodes a COL1A1/PDGFB transcript of which the product
contains the entire sequences for the processing of PDGFB. It is
postulated that such rearrangements release the PDGFB from its
physiologic control and unscheduled production of PDGFB creates
an autocrine mechanism responsible for the development of DFSP.
NIH 3T3 transformation by the rearranged human PDGFB gene is
shown to produce a growth factor with autocrine and paracrine
effects blocked by inhibitors of PDGFB activity (Greco et al, 1998).
PDGF isoforms are considered to be the principal mediators of
mesenchymal cell proliferation, including dermal ®broblasts (Ross
et al, 1986). Several studies suggest that the PDGFB signaling
pathway is implicated in various neoplastic conditions (Robbins et
al, 1982; Devare et al, 1983; Peres et al, 1987; Shamah et al, 1993;
Carroll et al, 1996). Although PDGF-induced signal transduction
pathways have been widely studied (Heldin et al, 1998), little is
known about the signaling pathways utilized in DFSP cells. To
further characterize DFSP cells, we investigated the mechanisms
involved in their increased mitogenic activity. The results suggest
that an extracellular signal related kinase (ERK) dependent pathway
is implicated in the increased mitogenic activity of DFSP cells.
MATERIALS AND METHODS
Materials Genistein, PD98059, SB202190, and calphostin C, which
were purchased from Calbiochem (La Jolla, CA), were dissolved in
dimethyl sulfoxide (DMSO). Controls were incubated with an equal
concentration of DMSO. The p44/42 ERK, phospho-speci®c ERK
(Thr202/Tyr204) rabbit polyclonal antibodies, phospho-speci®c Elk-1
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(Ser383), and puri®ed Elk-1 fusion protein were obtained from New
England Biolabs (Beverly, MA). Monoclonal anti-b-actin antibodies
were purchased from Sigma.
Cell cultures The cultured DFSP tumor cells were derived from ®ve
patients in whom the diagnosis had been established both clinically and
histologically, as described previously (Kikuchi et al, 1993). As controls,
we used normal dermal ®broblast cell strains derived from normal skin
obtained at the time of tumor resection. Dermal ®broblasts were also
grown from explants of skin biopsies from ®ve healthy donors, following
institutional approval and informed consent. Cells were cultured in
minimum essential medium (MEM) supplemented with 10% fetal bovine
serum (FBS) (Ihn et al, 1996; Ihn and Trojanowska, 1997; Ihn et al,
1997). Fibroblast cultures independently isolated from different
individuals were maintained as monolayers at 37°C in an atmosphere of
5% CO2 and 95% air (Ihn et al, 1996; 1997; Ihn and Trojanowska,
1997). Cells under the ®fth subpassage were used for the experiments.
DNA synthesis The cells (2 3 104 per well) were plated in 24-plates
in MEM with 10% FBS and grown to con¯uency, followed by 24 h
incubation in MEM with 0.1% bovine serum albumin (BSA). Then, the
cells were incubated with or without various concentrations of genistein,
PD98059, or calphostin C for 24 h in the absence of serum and were
labeled with [3H]-thymidine (®nal concentration 1 mCi per ml; New
England Nuclear, Boston, MA) for 2 h. The cell layers were washed
three times with cold phosphate-buffered saline (PBS) and ®ve times
with ice-cold 5% trichloroacetic acid and dissolved in 500 ml of 0.1 N
NaOH/0.1% sodium dodecyl sulfate. An aliquot of this extract was
counted in a Beckman scintillation counter (Ihn and Tamaki, 2000a).
Transfections and constructs Transient transfections were
performed as described previously (Ihn et al, 1996; 1997; Ihn and
Trojanowska, 1997). Cells were transfected using a lipofection technique
(FuGeneTM 6 Transfection Reagent, Boehringer Mannheim,
Indianapolis, IN) with various amounts of constructs (Ihn and Tamaki,
2000b; 2000c). The plasmid encoding the ERK2 [p42 mitogen-activated
protein kinase (MAPK)] cDNA in which the Thr183 and Tyr185 required
to be phosphorylated for activity were replaced with either glutaminic
acid or alanine and phenylalanine, thus rendering the protein inactive
(David et al, 1995; Ihn and Tamaki, 2000a). pSV-b-galactosidase control
vector (Promega, Madison, MI) was transfected to visualize transfection
ef®ciency. The cells were maintained in serum-free MEM and 0.1%
BSA for 24 h and the DNA synthesis was determined as described
above.
Immunoblotting For the preparation of cell lysates from the cultured
DFSP tumor cells and normal dermal ®broblasts, cells were placed in
MEM and 0.1% BSA for 24 h. Then, the medium was removed and the
cells were washed with PBS. The cells were lyzed by scraping into a
solubilization buffer [50 mM Tris±HCl, pH 8, 150 mM NaCl, 2 mM
ethylenediamine tetraacetic acid (EDTA), 50 mM NaF, 1% Triton X-
100, 1 mM sodium orthovanadate, 0.2 mM phenylmethylsulfonyl
¯uoride, 10 mg per ml aprotinin, 10 mg per ml leupeptin, and 10 mg per
ml pepstatin]. The lysates were incubated at 4°C for 30 min and then
centrifuged for 5 min at 4°C. Protein concentrations of lysates were
determined using a Bio-Rad (Hercules, CA) protein assay, as
recommended by the manufacturer. Immunoblotting was performed as
described previously (Ihn and Trojanowska, 1997; Ihn and Tamaki,
2000a; Ihn et al, 2001). Brie¯y, cell lysates (20 mg) obtained from cells
were subjected to electrophoresis on 10/20% gradient sodium dodecyl
sulfate polyacrylamide slab gels, and then electrotransferred from the gels
onto nitrocellulose sheets. The nitrocellulose sheets were incubated
overnight with the indicated primary antibodies. Bound antibodies were
detected with horseradish-peroxidase-conjugated antirabbit IgG and
immunoreactive bands were visualized with enhanced chemi-
luminescence (Amersham, Arlington Heights, IL) as described previously
(Ihn and Trojanowska, 1997; Ihn and Tamaki, 2000a).
Immuno¯uorescence Immuno¯uorescence analysis was performed as
described previously (Shuai et al, 1992). In brief, the cultured DFSP
tumor cells and normal dermal ®broblasts were cultured in eight-well
tissue culture chamber slides. After cells were placed in MEM and 0.1%
BSA for 24 h, the medium was removed and the cells were washed with
PBS and ®xed in 3.7% formaldehyde/PBS for 10 min. After two washes
with PBS, cells were incubated for 30 min in PBS containing 10% FBS.
Cells were permeabilized with 0.5% Triton-X. An antibody against ERK
was added and the slides were incubated for 1 h at 37°C. After three
washes, a ¯uorescein-conjugated secondary antibody was added and the
slides were incubated for 1 h at 37°C.
ERK activity assays Kinase assays were performed as described
previously (Chin et al, 1999) with minor modi®cations. Brie¯y, cells
were lyzed in buffer containing 20 mM Tris±HCl, pH 7.5, 150 mM
NaCl, 1 mM EDTA, 1 mM ethyleneglycol-bis(b-aminoethyl ether)-
N,N,N¢,N¢-tetraacetic acid, 1% Triton X-100, 2.5 mM sodium
pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na3VO4, 1 mg per ml
leupeptin, and 1 mM phenylmethylsulfonyl ¯uoride. Protein concen-
trations were determined as described for immunoblotting. Total protein
(200 mg) samples were incubated with phospho-speci®c ERK (Thr202/
Tyr204) rabbit polyclonal antibody overnight on a rocker at 4°C. Protein
A-Sepharose beads were then added to immunoprecipitate the activated
ERK complex. The immunoprecipitate pellets were incubated with 1 mg
of Elk-1 fusion protein in the presence of 100 mM ATP and a kinase
buffer containing 25 mM Tris-HCl, pH 7.5, 5 mM b-glycerophosphate,
2 mM dithiothreitol, 0.1 mM Na3VO4, and 10 mM MgCl2. The
reaction was terminated with sodium dodecyl sulfate loading buffer. The
samples were analyzed on 10/20% gradient sodium dodecyl sulfate
polyacrylamide slab gels as described in Immunoblotting. ERK activity was
assayed by detection of phosphorylated Elk-1 using a phospho-speci®c
Elk-1 rabbit polyclonal antibody (1:1000). After overnight incubation
with the primary antibody at 4°C, the membrane was incubated for 1 h
with a horseradish-peroxidase-conjugated antirabbit secondary antibody.
The proteins were subsequently detected using LuminoGLO (New
England Biolabs) as described previously (Ihn and Trojanowska, 1997;
Ihn and Tamaki, 2000a).
Statistical analysis Statistical analysis was carried out with the Mann±
Whitney test for the comparison of means. p-values less than 0.05 were
considered signi®cant.
RESULTS
DFSP cells showed increased mitogenic activity To
determine whether DFSP cells have increased mitogenic activity
compared with normal dermal ®broblasts, we measured the
incorporation of [3H]-thymidine by DFSP cells and normal
dermal ®broblast cultures in the absence of serum. The mean
[3H]-thymidine incorporation in serum-free MEM for each dermal
®broblast strain was arbitrarily set at 100%, and the [3H]-thymidine
incorporation for DFSP cells was estimated as a percentage ratio in
each experiment. As shown in Fig 1(A), DFSP cells showed
increased mitogenic activity. The mitogenic activity of DFSP cells
showed 200%±300% increases in DNA synthesis compared with
normal dermal ®broblasts.
The effect of a tyrosine kinase inhibitor on the increased
DNA synthesis of DFSP cells Previous studies reported that
PDGF signaling involved tyrosine phosphorylation in various types
of cells (Heldin et al, 1998). Therefore, we investigated the effects
of a tyrosine kinase inhibitor on the increased DNA synthesis of
DFSP cells. DFSP cells and normal dermal ®broblasts were treated
with a tyrosine kinase inhibitor, genistein. Pretreatment of DFSP
cells with genistein (30 mg per ml for 1 h) markedly decreased
[3H]-thymidine incorporation (Fig 1A). Pretreatment of normal
dermal ®broblasts with genistein also decreased [3H]-thymidine
incorporation by almost 60%. Furthermore, pretreatment of
®broblasts with PD98059, a speci®c ERK pathway inhibitor
(30 mM for 1 h), inhibited increased [3H]-thymidine incorporation
of DFSP cells (Fig 1A). Pretreatment of normal dermal ®broblasts
with PD98059 also decreased [3H]-thymidine incorporation. On
the other hand, pretreatment with calphostin C, a protein kinase C
inhibitor (5 mM), or SB202190, a p38 MAPK inhibitor (10 mM),
had no effect on the increased mitogenic activity of DFSP cells or
[3H]-thymidine incorporation of normal dermal ®broblasts
(Fig 1A). Furthermore, pretreatment of DFSP cells with
genistein (Fig 1B) or PD98059 (Fig 1C) inhibited increased
mitogenic activity of DFSP cells in a dose-dependent manner.
These results suggest that increased DNA synthesis of DFSP cells is
mediated via an ERK-dependent pathway.
Constitutive nuclear localization of ERK in DFSP
cells The localization of ERK was investigated using
immuno¯uorescence analysis wih serum-deprived DFSP cells and
normal human dermal ®broblasts. As shown in Fig 2(A), ERK was
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located in the cytoplasm of normal ®broblasts without stimulation.
ERK was constitutively located in the nucleus in DFSP cells,
however (Fig 2C). ERK blocking peptide was used to preabsorb
the antibody, which indicated that the staining was speci®c
(Fig 2E).
Constitutive tyrosine phosphorylation of MAPK in DFSP
cells The constitutive phosphorylation of ERK in DFSP cells
was investigated using serum-deprived DFSP cells and normal
human dermal ®broblasts. Detection of the phosphorylated
forms of ERK was performed with antibodies speci®c for the
phosphorylated sites (corresponding to Thr202/Tyr204) of the
p44 and p42 ERK. Immunoblotting of whole cell extracts
detected that constitutive ERK Thr202/Tyr204 phosphorylation
occurred in DFSP cells (Fig 3A). Slight phosphorylation of
ERK was also detected in some normal dermal ®roblasts
(Fig 3A, lanes 1, 2). Antibodies against ERK were also used to
determine the protein concentrations of ERK in DFSP cells and
Figure 1. Mitogenic activity of DFSP cells. (A) DFSP cells showed
increased mitogenic activity. The incorporation of [3H]-thymidine by
DFSP cells and normal dermal ®broblast cultures in the absence of serum
was measured. The mean [3H]-thymidine incorporation (cpm) in serum-
free MEM for each dermal ®broblast strain was arbitrarily set at 100%,
and the [3H]-thymidine incorporation for DFSP cells was estimated as a
percentage ratio in each experiment. The effects of genistein (30 mg per
ml), PD98059 (30 mM), calphostin C (5 mM), or SB202190 (10 mM)
were estimated as a percentage ratio. Pretreatment of DFSP cells with
genistein markedly decreased the increased [3H]-thymidine incorporation
in DFSP cells. Furthermore, pretreatment of DFSP cells with PD98059
inhibited the increased [3H]-thymidine incorporation in DFSP cells.
Pretreatment with calphostin C or SB202190, however, had no effect on
the increased mitogenic activity of DFSP cells. (B) Pretreatment of DFSP
cells with genistein (0.1±30 mg per ml) decreased the increased [3H]-
thymidine incorporation in DFSP cells in a dose-dependent manner. (C)
Pretreatment of DFSP cells with PD98059 (0.1±30 mM) decreased the
increased [3H]-thymidine incorporation in DFSP cells in a dose-
dependent manner. The means 6 SD for four separate experiments are
shown. Comparisons of the [3H]-thymidine incorporation (cpm) were
made between DFSP cells and normal dermal ®broblasts (*p < 0.01).
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normal dermal ®broblasts. Immunoblotting of whole cell
extracts demonstrated that DFSP cells and normal dermal
®broblasts had an equivalent amount of ERK (Fig 3A). We
next examined whether ERK phosphorylation detected in
DFSP cells was associated with increased ERK activity using
an immunocomplex kinase assay. Increased ERK activity was
also detected in DFSP cells (Fig 3B).
The expression of the dominant negative mutant MAPK
represses the increased DNA synthesis of DFSP cells To
further con®rm the role of MAPK in the growth regulation of
DFSP cells, transient transfection of the dominant negative mutant
ERK into DFSP cells and normal dermal ®broblasts was performed.
As shown in Fig 4, transient transfection of the dominant negative
mutant ERK in normal dermal ®broblasts decreased their [3H]-
Figure 2. Constitutive nuclear localization of ERK in DFSP cells. The localization of ERK was investigated with immuno¯uorescence analysis
using serum-deprived DFSP cells and normal human dermal ®broblasts as described in Materials and Methods. ERK was located in the cytoplasm of
normal ®broblasts without stimulation (A). ERK was constitutively located in the nucleus in DFSP cells, however (C). ERK blocking peptide was used
to preabsorb the antibody (E). Cells were counterstained with 4,6-diamidino-2-phenylindole to visualize nuclei (B, D, F).
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thymidine incorporation by almost 50% in a dose-dependent
manner. Furthermore, transient transfection of the dominant
negative mutant ERK in DFSP cells also abolished increased
[3H]-thymidine incorporation of DFSP cells.
DISCUSSION
PDGF is a potent stimulator of growth and motility of connective
tissue cells, such as ®broblasts and smooth muscle cells (Ross et al,
1986). It is a dimeric molecule consisting of disul®de-bonded A-
and B-polypeptide chains. Homodimeric (PDGF-AA, PDGF-BB)
as well as heterodimeric (PDGF-AB) isoforms exert their effects on
target cells by binding with different speci®cities to two structurally
related protein tyrosine kinase receptors, denoted the a- and b-
receptors (Hart et al, 1988; Heldin et al, 1988). PDGF-AA induces
aa receptor dimers, PDGF-AB aa or ab receptor dimers, and
PDGF-BB all three possible combinations of receptor dimers
(Bishayee et al, 1989; Heldin et al, 1989; Seifert et al, 1989).
The intracellular transduction of signals involves direct inter-
actions between components in the different signaling pathways.
Such interactions are exerted by speci®c domains, such as Src
homology 2 domains and phosphotyrosine binding domains, which
recognize phosphorylated tyrosine residues in speci®c environ-
ments, SH3 domains, which recognize proline-rich regions, and
pleckstin homology domains, which recognize membrane phos-
pholipids (Schlessinger, 1993; Pawson and Scott, 1997). More than
10 different SH2-domain-containing molecules have been shown
to bind to different autophosphorylation sites in the PDGF a- and
b-receptors, including signal transduction molecules with enzy-
matic activity such as phosphatidylinositol 3¢ kinase (PI3-kinase),
phospholipase C-g (PLC-g), the Src family of tyrosine kinases, the
tyrosine phosphatase SHP-2, GTPase activating protein (GAP) for
Ras, as well as adaptor molecules such as Grb2, Shc, Nck, Grb 7,
and Crk, and signal transduction and activators of transcription
(Stats) (Heldin et al, 1998). Activation of Ras by the PDGF b-
receptor occurs by direct binding of Grb2/Sos1 to the phosphoryl-
ated Tyr716 of the receptor, or binding of Grb2/Sos1 to
phosphorylated molecules bound to the receptor, like Shc or
SHP-2 (Schlessinger, 1993; Arvidsson et al, 1994; Benjamin and
Jones, 1994; Li et al, 1994; Yokote et al, 1994). Ras activation,
leading to activation of the MAP kinase cascade, has been shown to
be of major importance for growth stimulation, and overactivity of
different components along this pathway has been shown to lead to
cell transformation (Seger and Krebs, 1995).
This study demonstrated that DFSP cells showed increased
mitogenic activity (Fig 1A). This result is consistent with a
previous report that showed that NIH 3T3 cells transfected with
DFSP DNAs showed increased mitogenic activity (Greco et al,
1998). It was also reported that NIH 3T3 cells transfected with
DFSP DNAs constitutively expressed the tyrosine-phosphorylated
PDGF b-receptor (Greco et al, 1998). Little about the mechanism
of the increased growth activity of DFSP cells has been clari®ed,
however. In this study, increased DNA synthesis of DFSP cells was
Figure 3. Constitutive tyrosine phosphorylation of MAPK in
DFSP cells. (A) The constitutive phosphorylation of ERK in DFSP
cells was investigated using serum-deprived DFSP cells and normal
human dermal ®broblasts. Detection of the phosphorylated forms of
ERK was performed with the antibody speci®c for the phosphorylated
site (corresponding to Thr202/Tyr204) of the p44 and p42 ERK as
described in Materials and Methods. Immunoblotting of whole cell extracts
demonstrated that constitutive ERK Thr202/Tyr204 phosphorylation
occurred in DFSP cells. Antibodies against ERK were also used to
determine the protein concentrations of ERK in DFSP cells and normal
dermal ®broblasts, which demonstrated that DFSP cells and normal
dermal ®broblasts have equivalent amounts of p44 and p42 ERK.
Protein loading was con®rmed using monoclonal anti-b-actin antibodies.
(B) Immunocomplex kinase assay. Whole cell lysates were analyzed for
ERK activity as described in Materials and Methods. ERK was assayed by
immunoprecipitation with phospho-speci®c antibody to ERK followed
by detection of phosphorylation of Elk-1 fusion protein at Ser383 by
immunoblotting using a phospho-speci®c Elk-1 antibody.
Figure 4. The expression of the dominant negative mutant ERK
repressed the increased [3H]-thymidine incorporation of DFSP
cells. Transient transfection of the dominant negative mutant ERK or
the empty vector into human dermal ®broblasts as described in Materials
and Methods. The mean [3H]-thymidine incorporation (cpm) in serum-
free medium for each dermal ®broblast strain transfected with 0.5 mg of
the empty vector was arbitrarily set at 100%, and the effects of the
transfection of the dominant negative mutant ERK into DFSP cells and
normal dermal ®broblasts were estimated as a percentage ratio at each
concentration. The means 6 SD for four separate experiments are
shown. Comparisons of the [3H]-thymidine incorporation (cpm) were
made between DFSP cells and normal dermal ®broblasts (*p < 0.01).
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signi®cantly diminshed by a tyrosine kinase inhibitor, genistein, in a
dose-dependent manner (Fig 1B). This result suggests that phos-
phorylation of tyrosine kinase is involved in increased mitogenic
activity of DFSP cells.
Next, we determined whether an ERK pathway was involved in
the increased mitogenic activity of DFSP cells, using two
independent approaches to block the ERK signaling pathway.
First, we utilized an MEK1-speci®c inhibitor, PD98059, which
blocks MEK1 activation by Raf, thus preventing downstream
activation of ERK, but does not inhibit JNK or p38 MAPK. In
addition, PD98059 has been shown to have little effect on other
kinases, including cAMP-dependent kinase and protein kinase C
(Dudley et al, 1995; Pang et al, 1995). In our study, pretreatment of
DFSP cells with PD98059 inhibited their increased [3H]-thymidine
incorporation (Fig 1C). Furthermore, transfection with the dom-
inant negative mutant ERK into DFSP cells abolished their
increased mitogenic activity (Fig 4).
MAPK modules are involved in the signal transduction of a wide
variety of signals in all eukaryotic organisms. In mammalian cells,
three well-characterized modules coexist: p44/p42 ERK, p38
MAPK, and JNK cascades (Cano and Mahadevan, 1995). The
p42/p44 ERK cascade plays a pivotal role in the re-entry of
®broblasts into the cell cycle (Pages et al, 1993). Both p42 and p44
ERK are activated by dual phosphorylation on threonine and
tyrosine residues, achieved via the dual-speci®city kinase MAP
kinase kinases (MEK) 1/2. Whereas MEK 1/2 remain permanently
in the cytoplasm, p42/p44 ERK are relocalized from the cytoplasm
to the nucleus upon stimulation (Chen et al, 1992). In ®broblasts, a
correlation exists between the mitogenic potency of a stimulus and
its ability to trigger p42/p44 ERK translocation (Chen et al, 1992).
In this study, immuno¯uorescent analysis revealed that ERK was
constitutively located in the nucleus in DFSP cells, although it was
located in the cytoplasm of normal ®broblasts without stimulation
(Fig 2). Moreover, immunoblotting analyses using phospho-spe-
ci®c ERK antibodies that detect only the Thr202/Tyr204-phos-
phorylated forms of ERK1/ERK2 demonstrated that constitutive
ERK Thr202/Tyr204 phosphorylation was detected in DFSP cells
(Fig 3). These results suggest that constitutive ERK Thr202/Tyr204
phosphorylation make continual ERK translocation from the
cytoplasm to the nucleus. SB202190, however, a p38 MAPK
inhibitor, had no effect on the increased mitogenic activity of DFSP
cells or [3H]-thymidine incorporation of normal dermal ®broblasts
(Fig 1A). Furthermore, increased phosphorylation of JNK was not
detected in DFSP cells (data not shown). These results suggested that
neither p38 MAPK nor JNK is involved in increased mitogenic
activity of DFSP cells.
The ERK pathway is the prototypical MAPK pathway induced
by other growth factor stimulation and it is implicated in the
regulation processes of cellular proliferation (Blumer and Johnson,
1994; Kyriakis et al, 1994). A recent study demonstrated that ERK
was heavily phosphorylated on tyrosyl residues and its activity was
elevated in human breast cancer compared to benign conditions
(Sivaraman et al, 1997).
It will be of great interest to determine whether similar activation
of ERK-dependent signaling pathways exists in other human
neoplasia, and our ®ndings may potentially have important clinical
implications in DFSP.
Furthermore, the downstream pathways of ERK, such as ELK-1,
Sap-1, c-Myc, p90rsk, MAPKAPK2, MNK1, and MNK2, have
been reported and some of them may in¯uence mitogenic activity
(Frost et al, 1997; Rausch and Marshall, 1999; Sears et al, 1999;
Knauf et al, 2001; Noguchi et al, 2001). Further studies are needed
to clarify the involvement of these kinases in increased mitogenic
activity of DFSP cells.
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